Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor Resources
Investor News
Share Price / Index
April 16, 2026
Not intended for U.S. and UK Media
Phase III study results with Bayer’s FXIa inhibitor demonstrating substantial reduction in ischemic stroke with no increase in ISTH major bleeding versus placebo published in New England Journal of Medicine
March 30, 2026
Not intended for U.S. and UK Media
Kerendia™ approved in EU for new indication in adult patients with heart failure with LVEF ≥40%
March 23, 2026
Not intended for U.S. and UK Media
Eylea™ 8 mg approved for third retinal indication in Japan
Discover More
